ArticleJournal of artificial organs : the official journal of the Japanese Society for Artificial Organs2023
Three-year experience of catheter-based micro-axial left ventricular assist device, Impella, in Japanese patients: the first interim analysis of Japan registry for percutaneous ventricular assist device (J-PVAD).
Article in Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Predictors of Bleeding After Percutaneous Left Ventricular Assist Device Support: Findings From the J-PVAD Registry.JACC. Advances · 2026Article
- DanGer shock criteria and outcomes in acute myocardial infarction-related cardiogenic shock treated with Impella: the J-PVAD registry.European heart journal · 2026Article
- Inhaled nitric oxide therapy is effective in improving right ventricular function in patients receiving ECPELLA support.General thoracic and cardiovascular surgery · 2026Article
- Impact of Initial Axillary Microaxial Flow Pump on Post-Myocardial Infarction Ventricular Septal Defect Management.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- The Role of Impella in Cardiogenic Shock in the Post-DanGer Shock Era.Biomedicines · 2025Review
- Survey on Japanese emergency physicians' awareness of advanced mechanical circulatory support upgrade therapy for patients with out-of-hospital cardiac arrest receiving extracorporeal cardiopulmonary resuscitation.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Article
- Phase-Specific Hemodynamic Criteria and Outcomes in Patients With Cardiogenic Shock Receiving Percutaneous Ventricular Assist Devices.Journal of the American Heart Association · 2025Article
- Contemporary optimal therapeutic strategy with escalation/de-escalation of temporary mechanical circulatory support in patients with cardiogenic shock and advanced heart failure in Japan.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Review
- Combined Risk Stratification With Patient Characteristics and Biomarkers in Patients Treated With the Impella for Cardiogenic Shock.Journal of the American Heart Association · 2025Article
- Protocol-Driven Best Practices and Cardiogenic Shock Survival in Asian Patients.Journal of the American Heart Association · 2025Article
- A case of destination therapy for post-fulminant myocarditis with myelodysplastic syndrome.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2025Article
- Anticoagulation with Nafamostat Mesilate During Impella Support: A Case Report.Medicina (Kaunas, Lithuania) · 2025Article
- The association between introduction of the micro-axial flow pump Impella in hospitals and in-hospital mortality in patients treated with extracorporeal membrane oxygenation: interrupted time-series analyses.Annals of intensive care · 2024Article
- Cardiogenic shock: all hail the RCT, long live the registry.Critical care (London, England) · 2024Article
- Changing Trends in Mechanical Circulatory Support Use and Outcomes in Patients Undergoing Percutaneous Coronary Interventions for Acute Coronary Syndrome Complicated With Cardiogenic Shock: Insights From a Nationwide Registry in Japan.Journal of the American Heart Association · 2023Article
- Complications and Outcomes of Impella Treatment in Cardiogenic Shock Patients With and Without Acute Myocardial Infarction.Journal of the American Heart Association · 2023Article
- Organ dysfunction, injury, and failure in cardiogenic shock.Journal of intensive care · 2023Review
- Sex-Related Differences in Short-Term Prognosis in Patients with Acute Myocardial Infarction-Related Cardiogenic Shock Receiving Impella Support in Japan: From the J-PVAD Registry.Medicina (Kaunas, Lithuania) · 2023Article
- Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Comprehensive Systematic Literature Review and Meta-Analyses.Journal of cardiovascular development and disease · 2023Review
- Pathophysiology and Management of Heart Failure in the Elderly.The International journal of angiology : official publication of the International College of Angiology, Inc · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 12 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catheter-based micro-axial ventricular assist device Impella® (Abiomed, Danvers, MA) has been used in Japanese patients with drug-refractory acute heart failure (AHF) since 2017. This is the first interim analysis of the ongoing Japan Registry for Percutaneous Ventricular Assist Device (J-PVAD) to investigate the safety and efficacy of Impella support. Between October 2017 and January 2020, 823 Japanese patients, who were treated with the Impella 2.5, CP, or 5.0 pump, were enrolled. The primary endpoints were safety profiles and cumulative 30-day survival. Among them, 44.8% of patients were acute myocardial infarction with cardiogenic shock. The Impella pumps were unable to implant in 4 patients. The Impella 2.5, CP, and 5.0 pumps were used in 72.4%, 6.2%, and 16.6%, respectively, and mean support duration was 8.1 ± 10.2 days. Combination use of Impella and venoarterial extracorporeal membrane oxygenation (VA-ECMO) was applied for 387 patients (47.3%). Pump stop occurred 22 patients (2.7%). Major adverse events included hemolysis (11.2%), hemorrhage/hematoma (6.1%), peripheral ischemia (1.6%), and stroke (1.6%). The overall 30-day survival was 62.2%. Survival of patients with single Impella support was significantly higher than patients with Impella combined with VA-ECMO support (81.1% vs 49.6%; p < 0.01), who had lower blood pressure, lower left ventricular ejection fraction, and higher degree of inotropic support. Results suggest that short-term outcome of Impella support for Japanese patients was favorable with acceptable safety profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.